Navigation Links
Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies, Finds Frost & Sullivan
Date:2/20/2013

MOUNTAIN VIEW, Calif., Feb. 20, 2013 /PRNewswire/ -- New wound care technologies that detect early wound healing and manage wound healing mechanisms are finding favor with physicians that are trying to determine suitable treatment protocols. Wound care management received a thrust from cost-effective and efficient technologically advanced products and therapies. Some wound care advancements that gained traction recently include wound dressings that offer controlled release of enzymes and antimicrobial agents, and silver nanocomposites that exhibit protective barrier and anti-inflammatory properties.

New analysis from Frost & Sullivan's (http://www.technicalinsights.frost.com) Wound Care Management Technologies research finds that wound care therapy developers are increasingly responding to the demand for more effective wound care solutions. Biotechnology, biomaterial, and tissue engineering-enabled innovations are some of the fastest growing technology segments in this market.

If you are interested in more information on this research, please email Britni Myers , Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Other popular innovations in wound management include honey-based dressings with antimicrobial, wound cleansing, and pain-free debridement properties, as well as tissue engineering constructs to promote wound healing. Combination medical devices that help deliver targeted wound care therapy to ensure safe and timely closure of wounds are also in demand.

Wound care specialists and podiatrists as well as general, vascular and orthopedic surgeons prefer cost-effective wound care solutions, while chronic wound patients and their caregivers seek faster and long-lasting wound healing solutions. Reacting to customer demand, manufacturers are adopting best practices to design wound dressings that provide tight control over the dressing's adsorption and fluid handling properties.

There is a surge in the number of wound healing technology platforms awaiting commercialization and multiple start-up firms and spin-offs from academia are working on procuring funds and partnerships for commercialization. Both Tier 1 and emerging companies are engaged in intense R&D to develop dressings that accelerate healing.

"Emerging companies that focus on every type of wound at each phase of the wound healing process will be able to provide innovative solutions," noted Frost & Sullivan Technical Insights Industry Analyst Prasanna Vadhana Kannan. "One of the noteworthy wound care solutions are advanced wound dressings that can assist in the complex task of tissue repair and efficiently remove bacterial biofilm formation."

Currently, there are no national or international standards to guide wound care dressing manufacturers, and the type of protocol adopted depends upon the physician's recommendation and patient's demand. This situation hinders the implementation and testing of affordable wound care platforms.

Standardization is vital since wound treatment relies heavily on proper wound bed preparation, the choice of wound dressings, and the patient's condition. Wound closure also depends on the use of appropriate products.

Researchers are striving to examine the importance of cell differentiation and tissue morphogenesis-based factors in faster wound healing. Manufacturers need greater clinical evidence to understand biological-mediated therapies and their role in improving the outcome of wound care.

"On the back of considerable research, wound care solutions are expected to have the capabilities to safeguard cells from apoptosis, and simultaneously stimulate rapid cell division and proliferation," noted Kannan. "A rising desire to achieve tissue regeneration rather than just wound closure encourages manufacturers to explore additional applications of wound healing technologies."

Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare, and LinkedIn, for the latest news and updates.

Wound Care Management Technologies, a part of the Technical Insights subscription, analyzes advances in the application of silver in microbial prophylaxis and treatment, advanced wound dressings and skin substitutes, biologic wound products, and hyperbaric oxygen as an adjunctive wound care treatment. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters and research services.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360-degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Wound Care Management Technologies
D4BE-54

Contact:
Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003
E: britni.myers@frost.com
Twitter: @Frost_Sullivan
Facebook: Frost & Sullivan

http://www.frost.com
http://www.technicalinsights.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lentigen Receives U.S. Orphan Drug Designation for Novel Gene Therapy for glioblastoma multiforme
2. Novelos Therapeutics Prices $5.5 Million Public Offering
3. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
4. RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
5. Frost & Sullivan Determines a Real and Urgent Need for Novel Cancer Diagnostics Tests
6. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
7. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
8. Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015
9. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
10. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
11. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch to ... - living - adjustment (COLA) is a bad deal for older and disabled Americans, ... index (CPI) would grow even more slowly than the conventional one that is currently ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), a leading health care ... unit of Constellation Inc., a move that will help the company better serve its ... Louis, the acquisition is expected to help MTS expand its presence in ...
(Date:7/20/2017)... ... ... “Fidget”: a fun-filled, action-packed memoir of adventures. “Fidget” is the creation of ... who was a summa cum laude graduate of Gardner Webb University. She has won ... her retirement from public school, Lynn continued to pursue her love for music through ...
(Date:7/18/2017)... ... 2017 , ... The results of an international clinical trial, led in part by a UC ... of muscular dystrophy holds promise for a subgroup of patients. , In a paper just ... at 53 study sites in 18 countries describe the clinical benefit of using the drug ...
(Date:7/18/2017)... ... July 19, 2017 , ... ... it’s Corporate Social Responsibility Initiative in the prestigious CEO World Awards®. The ... organizational performance, new products and services, CEO case studies, corporate social responsibility, and ...
Breaking Medicine News(10 mins):